This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent. Top assignees: National Institute of Health and Medical Research, Université Paris Descartes, Université Paris Diderot-Paris 7. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:




Years Active: 2019
Title: Sebastien Lacroix-Desmazes: Innovator in Mucosal Vaccination
Introduction
Sebastien Lacroix-Desmazes is a notable inventor based in Paris, France. He has made significant contributions to the field of immunology, particularly in the area of mucosal vaccination. His innovative approaches aim to enhance immune tolerance through advanced pharmaceutical methods.
Latest Patents
Lacroix-Desmazes holds a patent titled "Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens." This invention focuses on methods and pharmaceutical compositions designed to induce immune tolerance by utilizing mucosal vaccination techniques. Specifically, it involves a method for inducing tolerance to a specific antigen in a subject by administering a therapeutically effective amount of a recombinant chimeric construct that includes a FcRn targeting moiety and an antigen-containing moiety.
Career Highlights
Throughout his career, Sebastien Lacroix-Desmazes has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris Descartes. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Lacroix-Desmazes has collaborated with notable colleagues, including Roberto Mallone and Slobodan Culina. These partnerships have further enriched his research endeavors and have led to significant advancements in the field of immunology.
Conclusion
Sebastien Lacroix-Desmazes is a pioneering inventor whose work in mucosal vaccination has the potential to transform immunological therapies. His innovative methods and collaborations highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile